Related Experiment Videos
Association between serum apolipoprotein C(II) concentration and coronary heart disease
Yariv Gerber1, Uri Goldbourt, Hofit Cohen
1Division of Epidemiology and Preventive Medicine, Sackler Medical Faculty, Tel Aviv University, Israel.
Background:
Apolipoprotein (Apo) C(II) plays an essential role in the metabolism of triglyceride-rich lipoproteins (TRLs) by activating lipoprotein lipase. Several studies have suggested that an abnormal concentration of Apo C(II) may serve as a marker for deficient TRL metabolism, a possible cause of coronary heart disease (CHD). The aim of the present study was to evaluate the association between Apo C(II) and the presence of CHD.
Methods:
A case-control study comparing 352 CHD patients and 395 controls was performed. Demographic, clinical, and laboratory characteristics were determined.
Results:
The CHD patients had a higher mean concentration of Apo C(II) than controls (5.3 mg/dl compared with 4.2 mg/dl, P < 0.001). Elevated serum Apo C(II) concentration was associated with CHD presence after adjustment for cardiovascular risk factors. The risk factor-adjusted odds ratio (OR) for CHD was 1.60 (95% CI: 1.31-1.94) per 1 mg/dl increment in Apo C(II), compared with a risk factor-adjusted OR of 1.05 (95% CI: 0.85-1.32) per 40 mg/dl increment in triglyceride concentration.
Conclusion:
Increased serum concentration of Apo C(II) may represent a more sensitive marker of CHD than high serum concentration of triglycerides. Confirmation in cohort studies in required to establish or refute the role of elevated serum Apo C(II) as a risk factor for CHD.